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The view is now emerging that, despite evidence that there
are a number of mechanisms involved in atherogenesis, the
contributions of elevated levels of atherogenic lipoproteins
containing apolipoprotein B-100, especially low-density
lipoproteins (LDL), are assuming a dominant role. Obser-
vations on genetic variants, such as loss-of-function muta-
tions at the PCSK9 locus, tell us that distinctly low levels of
LDL are attended with a very low risk for atherosclerotic
heart disease, suggesting that therapeutic goals should be
lower than those established in the past (1). It is also
apparent that a signiﬁcant number of patients are either
unable to reach appropriate levels of LDL with currently
available therapeutic agents or are intolerant of those
medications. The 3-hydroxy-3-methylglutaryl coenzyme ASee page 1154(HMG-CoA) reductase inhibitors (“statins”) are the most
potent agents now available. Their activity can be enhanced
dramatically by the addition of emerging antibodies that
disable the PCSK9 protein, with the effect of increasing the
functional endurance of the receptors. However, both of
these therapeutic strategies are dependent on the existence of
a functionally signiﬁcant population of receptors and, failing
the discovery of small-molecule inhibitors of PCSK9, will
require the employment of expensive antibody therapeutics if
that target is to be included. Thus, for those patients who
lack sufﬁcient numbers of functional receptors or who are
drug intolerant, new avenues of therapy are needed.
In this issue of the Journal, Ballantyne et al. (2) introduce
a novel dual-effect, small-molecule therapy that plays 2
crucial roles in the central control pathways for lipids and
carbohydrates. The ﬁrst involves inhibition of adenosine
triphosphate citrate lyase, the enzyme crucial for the
production of adenosine triphosphate citrate essential to the
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vation of adenosine monophosphate activated protein kinase
(AMPK)dresident in the liver, striated muscle, and the
braindthe protein that is at the heart of the directional
control of energy substrates. It is effectively a sensor of the
energy-depleted form of adenosine triphosphate (ATP) (i.e.,
AMP) and thus is able to redirect energy substrates at the
time of need, such as during skeletal muscle activity. Its effect
is concerted in several coordinated pathways, all of which
increase the uptake and consumption of glucose and fatty
acids and inhibit anabolic processes. These include increased
beta-oxidation of fatty acids, gluconeogenesis, and increased
numbers of mitochondria in the cell (3). There is evidence
that AMPK also plays a role in the increased metabolic
activity of mitochondria, at least in response to acute exercise,
an activity that would contribute further to the consumption
of fatty acids. In this setting, AMPK increases the activity
of the peroxisome proliferator-activated receptor (PPAR)-
gamma coactivator-1 (PGC)-alpha, a transcription factor
with a recognized role in the regulation of genes involved in
ketogenesis and gluconeogenesis. This activity suggests that
possible synergy could exist with PPAR-gamma agonists. At
the same time, the activation of AMPK decreases the
synthesis of cholesterol and of fatty acids and, thus, of
triglycerides. Also, the complement of the Glut-4 glucose
transporter in striated red muscle ﬁbers is increased by
translocation, an effect associated with exercise (4,5). In
addition, AMPK appears to increase the phosphorylation of
glucose by hexokinase in muscle cells, favoring the ﬂux into
muscle (4).
This array of metabolic-regulatory activities would suggest
multiple effects of this agent, clearly on cholesterol metabo-
lism, but also on diabetes and hypertriglyceridemia. The
clinical trial excluded individuals with diabetes, so the former
effect could not be appreciated. However, a suggestion that it
may be expected arises from the observation that levels of
insulin decreased among hyperinsulinemic individuals.
Clearly, trials in diabetic patients should be undertaken
because of the relationship between insulin resistance/overt
diabetes and arteriosclerotic heart disease. Because many of
the subjects did not have hypertriglyceridemia of signiﬁcance,
and because hypertriglyceridemia may result from different
underlying metabolic derangements, the absence of a broad
effect on triglyceride levels in this trial may also not reﬂect the
whole potential impact on triglyceride metabolism.
The striking effect on LDL cholesterol levels, however, is
the 27% reduction in at the upper dosage level which
appears to be well tolerated, at least in the very short term,
which suggests that this new avenue may have true beneﬁt in
individuals with elevated LDL cholesterol levels. The
particular appeal of this strategy is that it might be expected
to be independent of statin effects, acting to deplete the
precursors of cholesterol and fatty acids. Thus, it might be
expected to be of use in individuals unresponsive to, or
intolerant of, statins. A caveat must be considered here,
however: If statin intolerance in some individuals comes
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1164from the depletion of isoprenoid compounds in the HMG-
CoA–mevalonate pathway, such as dolichol, or from
decreased prenylation of proteins, then upstream impedance
in the pathway could produce a similar effect. Further
experience with agents in this class will inform this in time.
Another phenotype of dyslipidemia in which beneﬁt may
be shown is familial combined hyperlipidemia, in which the
underlying mechanism is thought to be overproduction of
very-low-density lipoproteins (VLDL), which are then
metabolized to LDL. This is believed to be the most prev-
alent disorder of circulating lipids now recognized, and it is
responsible for a signiﬁcant part of the burden of coronary
artery disease in Europe and North America. Reduction of
triglyceride synthesis and increased oxidation of fatty acids in
the liver would be expected to decrease the ﬂux of triglyc-
erides in VLDL, and the reduction in cholesterol synthesis
would be expected to reduce intrahepatic cholesterol, up-
regulating LDL receptors in receptor-competent individ-
uals. It will be important to determine whether synergistic
activity will occur when this agent is administered with other
lipid-lowering medications, especially statins.
The report is very early in the development of this agent,
restricted to short-term data on only 177 subjects, and
excludes individuals with diabetes and other metabolic
disorders of importance. Observation for adverse events will
have to be extended for a long period and in much larger
cohorts, because some adverse events may be observed only
in patients with predisposing genetic factors. For example,
there are data suggesting that ATP citrate lyase has a role in
regulating histone acetylation and perhaps in other biolog-
ically important acetylation processes, even affecting cell
growth and replication. The long-term effect of this action
must be appreciated in human subjects.
The exciting aspect of the development of this new agent
is that it embarks on a new avenue of metabolic regulation.
Another example of targeted therapy is the emergence ofcompounds that inhibit SRBI protein activity (6). As the
molecular participants in pathways such as the AMPK
regulatory system become characterized in detail, and the
detailed 3-dimensional structure of key elements such as
ATP citrate lyase and AMPK become known (the proteins
are dimeric and trimeric, respectively, and are now charac-
terized in detail), small-molecule inhibitors or activators can
be identiﬁed by array technology. It is expected that the
application of the understanding of crucial pathways of
metabolic regulation will reveal a host of new targets for
rational therapeutic intervention.
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